Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Twist Bioscience Corporation and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research

Published 05/31/2023, 08:09 AM
Updated 05/31/2023, 08:11 AM
Twist Bioscience Corporation (TWST) and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research

Twist Bioscience Corporation (TWST) and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research

Twist Bioscience (NASDAQ:TWST) Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and CeGaT GmbH, a global provider of sequencing services for research, clinical studies, and human genetic diagnostics, today announced the launch of the Twist Alliance CeGaT RNA Fusion Panel, which is designed to detect RNA fusions and conduct transcript variant analysis for oncology research. RNA fusions are the result of parts from two different genes fusing together. This can happen during chromosomal arrangements, which frequently occur in cancers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005318/en/

“RNA fusions often go undetected by PCR sequencing methods if one of the gene parts is unknown and by whole transcriptome analysis, especially when the sample input is degraded,” said Dirk Biskup, Ph.D., managing director and co-founder of CeGaT. “We combined Twist's RNA Library Prep and target enrichment capabilities with our expert knowledge in tumor diagnostics and panel design. This is how together we created the Twist Alliance CeGaT RNA Fusion Panel enriching for over one hundred and fifty fusion genes. This panel is designed to deliver high-quality results, even from low-input samples.”

RNA fusions are known drivers of disease evolution and progression, making them key biomarkers for oncology studies. Detection of fusion events can be used by researchers to identify molecular subtypes of cancers, which could inform studies concerning precision treatment options. They can also be used by researchers to monitor for minimal residual disease (MRD) following treatment.

“As we expand into the RNA market, the Twist Alliance CeGaT RNA Fusion Panel adds to our growing RNA sequencing toolset, which includes the Twist RNA Exome, RNA Library Prep and rRNA and Globin Depletion Kit. It also adds to our growing portfolio of DNA and RNA products that could be used to support precision medicine research in oncology,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By partnering with CeGaT, we are able to offer researchers an end-to-end library prep workflow with Twist RNA Library Prep and fusion capture and CeGaT’s software analysis.”

About Twist Alliance CeGaT RNA Fusion Panel

The Twist Alliance CeGaT RNA Fusion Panel utilizes Twist RNA Library Prep and fusion capture along with CeGaT’s software analysis to detect fusions in specific tumor types and identify novel fusion events. The panel includes over one hundred and fifty fusion genes.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.